Oxford BioDynamics
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Rowan Place, John Smith Drive 3140, Oxfo...Phone Number
+44 1865518910Website
www.oxfordbiodynamics.comRevenue
<$5 MillionStock Symbol
OBDIndustry
About Oxford BioDynamics
Oxford BioDynamics PLC specializes in clinical smart tests based on EpiSwitch technology, aimed at assisting individuals in making informed health decisions while addressing healthcare costs. Their products include the EpiSwitch CiRT and EpiSwitch PSE, which provide high-accuracy cancer detection and therapeutic guidance for cancer treatments. The EpiSwitch platform enables the application of 3D genomics for precision medicine at scale. Their services are particularly valuable for patients facing cancer-related health challenges.Explore more
Oxford BioDynamics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Oxford BioDynamics
Compare insights from companies similar to Oxford BioDynamics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Oxford BioDynamics Tech Stack
A closer look at the technologies used by Oxford BioDynamics
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Oxford BioDynamics
Sign Up For FreeTo access detailed company insights
Oxford BioDynamics PLC specializes in clinical smart tests based on EpiSwitch technology, aimed at assisting individuals in making informed health decisions while addressing healthcare costs. Their products include the EpiSwitch CiRT and EpiSwitch PSE, which provide high-accuracy cancer detection and therapeutic guidance for cancer treatments. The... Read More
